Fresenius Kabi USA Launches Treatment for Acetaminophen Overdose

Acetylcysteine Injection Now Available

January 8, 2013

Schaumburg, Ill. Jan. 8, 2013 - Fresenius Kabi USA today announced the launch of Acetylcysteine Injection. The product is indicated to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen.

"The introduction of Acetylcysteine Injection provides our customers with an alternative to the branded option available to them until now. The addition of Acetylcysteine Injection expands an already extensive critical care portfolio of APP products," said John Ducker, president and chief executive officer of Fresenius Kabi USA.

Acetylcysteine Injection was developed by InnoPharma, Inc. As part of its approval, InnoPharma received 180 day exclusivity for Acetylcysteine Injection. Fresenius Kabi has a licensing agreement with InnoPharma to sell, market and distribute Acetylcysteine Injection in the United States.

Acetylcysteine Injection is therapeutically equivalent to the reference-listed drug Acetadote®. According to IMS Health, in 2011, U.S. sales for Acetadote were approximately $43 million.

About Acetylcysteine Injection

Acetylcysteine Injection is indicated to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen.

About Fresenius Kabi

Fresenius Kabi is focused on the care of critically and chronically ill patients inside and outside the hospital. Its portfolio of products comprises a wide range of IV drugs, infusion therapies, clinical nutrition products as well as the related medical devices and blood transfusion technologies. With a corporate philosophy of "Caring for Life," the company's goal is to improve the patient's quality of life. Fresenius Kabi AG is a 100 percent subsidiary of the health care group Fresenius SE & Co. KGaA. For more information, visit

In the United States, APP, a division of Fresenius Kabi USA markets a broad portfolio of specialty pharmaceutical products with a focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets for use in hospitals, long-term care facilities, alternate care sites and clinics. For more information, visit

Forward-Looking Statement

The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2010 and other documents the company has filed with the Securities and Exchange Commission. The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company's expectations.

APP Contact
Matt Kuhn
Senior Director, Communications & Government Affairs
Fresenius Kabi USA